Things move real slow in Tokman land. I want to see some progress with products proclaiming Picop. Want to see something real that I can touch besides Cellulon. With a three dollar tax credit going forward and the patents growing more valuable every day we stagnate waiting for some real announcements. Need something besides smiling BOD members. Want to see the F500 is serious with an order. Want to see UPS happy enough to follow up. Want to see an auto HUD with PicoP. Aren't we the leaders in Display Tech, even if it is us who says so.
You have to think of it as positive because we rarely get any information from the company. If it weren't required by law they wouldn't talk to us at all.
Cost efficient is great, results are what is going to sell the platform. Cheaper is good if it works as well or better than the competition and P2 hasn't proved that yet. Data, data, data, not peer review forever. MOVE Dr. Kim.
yep, big pharma is looking at ADXS real close right now and like what the see. Lots more upside there and focused management. The talk is get on board by some of the bigs. I thought we were there last year with the dwarfing and cockiness of Dr. Kim. You never know.
Reality for me is that you have to get to $20 in order to get $40, and that is a long way off in my mind. As we sit here at $3, with an ever increasing patent value, and a growing revenue stream, I would be offering Tokman $10 a share and a "King of Display" title and titles for all the BOD members just to sew all this up. I hope they are much greedier than me and want the moon, if it comes to that.
This board is almost solid Dr. Kim worshipers, so you will not find many good conversations giving both sides a fair view. I seem to be about the same as FDA in my thinking. I have been blasted for our business execution quotes. Good luck, I don't post opinions much any more.
So true sara. These guys are blind when it comes to INO. Focus is the problem, we seem to be playing catch up and all over the place. Data, data, data and partnerships. By the time they figure it out it will be ten more dilutions and still searching.
Where I feel the company is most vulnerable to take over or cheap buyout attempts. All pieces are in place and lasers (the big issue) appears to be behind us. Now that all the work is done and everything is in place the big money will be looking. Great ASM validating what we knew would come and now we are ripe and looking sweet to the big players. Patents have grown substantially in the last year and are worth sooo much more than they show. We are being held down for a good reason, and we have no institutional investment worth talking about. Lord how I wish we had a poison pill.
And shows no respect for our ability to enforce them. Sometimes you gotta punch someone in the face, so to speak, just to get their attention.
NASDAQ sight on Friday showed almost as many institutional declines as buyers. Dr. Kim has to attract some BP validation and support for our platform. Good Post FDA.
Fda, do you know how many times I have brought this very subject up here? You are talking to a herd of Dr. Kim worshipers who can't see the business end this company. The are a nickle and dime crowd that scream, go it alone, more money for us, and miss the big picture. ADXS has a great management team that is doing what we should be doing. We have some of the best talent in the field and they are coming to work for INO because we have something special. We are falling short in the business end by not focusing on our "low hanging fruit" and bringing a plethora of offerings to the market. Without BP support, this road is a dangerous one for a small bio like INO. Constant dilution is not a good thing. NASDAQ